Exelixis
EXEL
#1615
Rank
โ‚ฌ9.47 B
Marketcap
33,86ย โ‚ฌ
Share price
-5.68%
Change (1 day)
64.79%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚ฌ0.63 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚ฌ2.16 Billion. , an increase over its 2023 earnings that were of โ‚ฌ0.23 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 โ‚ฌ0.62 B164.69%
2023 โ‚ฌ0.23 B9.89%
2022 โ‚ฌ0.21 B-20.33%
2021 โ‚ฌ0.26 B124.82%
2020 โ‚ฌ0.11 B-67.14%
2019 โ‚ฌ0.36 B-11.94%
2018 โ‚ฌ0.41 B185.09%
2017 โ‚ฌ0.14 B-325.82%
2016 -โ‚ฌ64.38 Million-58.12%
2015 -โ‚ฌ0.16 Billion-37.61%
2014 -โ‚ฌ0.25 Billion9.75%
2013 -โ‚ฌ0.23 Billion65.96%
2012 -โ‚ฌ0.14 Billion-291.63%
2011 โ‚ฌ70.58 M-195.59%
2010 -โ‚ฌ73.84 Million-42.17%
2009 -โ‚ฌ0.13 Billion-18.98%
2008 -โ‚ฌ0.16 Billion-6.99%
2007 -โ‚ฌ0.17 Billion46.3%
2006 -โ‚ฌ0.12 Billion33.25%
2005 -โ‚ฌ86.93 Million-30.92%
2004 -โ‚ฌ0.13 Billion44.29%
2003 -โ‚ฌ87.21 Million12.86%
2002 -โ‚ฌ77.28 Million22.79%
2001 -โ‚ฌ62.94 Million60.14%
2000 -โ‚ฌ39.3 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚ฌ3.82 B 511.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ7.28 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ13.72 B 2,096.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ7.69 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ4.22 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ15.99 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ6.36 B 918.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ41.09 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ26.63 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA